TP53 and breast carcinoma: The developed NSPs were evaluated in terms of physicochemical properties that allowed us to select the best NSPs which were then further investigated for in vitro release, in vitro antioxidant and cytotoxicity against MCF7 breast cancer cell lines; this was then further confirmed by caspase 3, 9 and p53 activities.